We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Tandem Diabetes Care, Inc. (TNDM - Free Report) shares rallied 7.7% in the last trading session to close at $17.53. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 31.4% loss over the past four weeks.
Tandem Diabetes scored a strong price increase, driven by investor’s optimism surrounding strong progress across its strategic initiatives, operational momentum and improving financial performance. The company shipped nearly 33,000 pumps worldwide in the second quarter of 2026, driven by the continued demand for Control-IQ, product innovations, and enhanced channel access. Tandem Diabetes also launched t:slim X2 Insulin pump compatibility with Abbott FreeStyle Libre 3 Plus Sensor across five international markets.
This company is expected to post quarterly loss of $0.26 per share in its upcoming report, which represents a year-over-year change of +16.1%. Revenues are expected to be $265.01 million, up 6.3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Tandem Diabetes Care, the consensus EPS estimate for the quarter has been revised marginally higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on TNDM going forward to see if this recent jump can turn into more strength down the road.
Tandem Diabetes Care belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Treace Medical Concepts (TMCI - Free Report) , closed the last trading session 0.4% lower at $4.56. Over the past month, TMCI has returned 2.9%.
For Treace Medical Concepts, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.26. This represents no change from what the company reported a year ago. Treace Medical Concepts currently has a Zacks Rank of #2 (Buy).
View the Zacks #1 Rank List
Image: Bigstock
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
Tandem Diabetes Care, Inc. (TNDM - Free Report) shares rallied 7.7% in the last trading session to close at $17.53. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 31.4% loss over the past four weeks.
Tandem Diabetes scored a strong price increase, driven by investor’s optimism surrounding strong progress across its strategic initiatives, operational momentum and improving financial performance. The company shipped nearly 33,000 pumps worldwide in the second quarter of 2026, driven by the continued demand for Control-IQ, product innovations, and enhanced channel access. Tandem Diabetes also launched t:slim X2 Insulin pump compatibility with Abbott FreeStyle Libre 3 Plus Sensor across five international markets.
This company is expected to post quarterly loss of $0.26 per share in its upcoming report, which represents a year-over-year change of +16.1%. Revenues are expected to be $265.01 million, up 6.3% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Tandem Diabetes Care, the consensus EPS estimate for the quarter has been revised marginally higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on TNDM going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Tandem Diabetes Care belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Treace Medical Concepts (TMCI - Free Report) , closed the last trading session 0.4% lower at $4.56. Over the past month, TMCI has returned 2.9%.
For Treace Medical Concepts, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.26. This represents no change from what the company reported a year ago. Treace Medical Concepts currently has a Zacks Rank of #2 (Buy).